St. Jude eyes larger patient group in new renal denervation study

January 30, 2013 by MassDevice staff

Medical device maker St. Jude Medical enrolls the 1st patient in a post-market study of its Enlightn renal denervation system, hoping to expand research to patients with less severe forms of hypertension.

St. Jude Medical's Enlighn renal denervation system

Medtech giant St. Jude Medical (NYSE:STJ) launched a new trial of its Enlightn renal denervation system, hoping to demonstrate the value of the technology in a larger clutch of patients.

Prior studies have generally focused on patients with "drug-resistant" hypertension, those with a systolic blood pressure reading above 160 mmHg despite treatment with 3 or more drugs. The new Enlightn II post-market study is eying the "uncontrolled" population, patients with a less severe form of hypertension.

Sign up to get our free newsletters delivered right to your inbox.

The new trial builds on the success of Enlightn I, in which researchers concluded that treatment with St. Jude's renal denervation system produced significant and sustained reduction in systolic blood pressure. Patients on average experienced a stable 26 mmHg reduction in blood pressure 6 months after treatment, according to a press release.